NK cell therapy

Artiva Biotherapeutics to present AlloNK cell therapy pipeline at Needham Healthcare Conference on April 15, 2026, advancing three ongoing autoimmune disease trials.

Global cell therapy manufacturing market projected to reach $14B by 2035, with FDA regulatory flexibility accelerating approvals and multiple biotech companies advancing scalable production capabilities.

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.

ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.